According to MedEfficiency, the TCC-EZ cast will act as a protective barrier for the open wounds that often develop on the undersides of diabetic patients’ feet, and help to greatly reduce the over 80,000 diabetes-related lower extremity amputations that are performed annually in the US, at a cost of over $2.5 billion for the hospital system.
The TCC-EZ also provides additional support and stability for the patient, thus reducing the likelihood of post-treatment injuries as well.
Ed Quilty, CEO of Derma Sciences, said: “Our goal is advancing wound care by uncovering novel technologies, empowering caregivers, and focusing on patients’ unmet needs.
“Helping to bring the TCC-EZ cast to market achieves all three. If we are able to increase adoption of a technology that is considered the gold standard for treatment of diabetic foot ulcers, we feel confident this will lead to fewer amputations.”